In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Previews (01/2011)

Executive Summary

A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Benlysta May Lead Wave Of New Approvals For Lupus Drugs," features profiles of Azano Pharmaceuticals, Resolve Therapeutics and SuppreMol. Plus these Start-Ups Across Health Care: biocrea, e(ye)BRAIN, MiCardia and Omthera Pharmaceuticals

You may also be interested in...



Resolve Therapeutics LLC

A growing number of competing companies are taking fresh approaches to treating lupus. Genentech and MedImmune, for instance, are each working on antibodies intended to directly bind the cytokine known as interferon-alpha, and inhibit its inflammatory effects. Start-up Resolve Therapeutics LLC is developing a compound intended to act in the same pathway as Genentech's and MedImmune's antibodies, but upstream of alpha-interferon. The idea is not to block production of interferon itself, but rather to block events that company founders believe trigger alpha-interferon production in lupus patients.

SuppreMol GMBH

SuppreMol GMBH is developing a recombinant version of human Fcy receptor FcyRIIb, now in Phase IIa for SLE. This candidate competes with membrane-bound Fcy receptors on immune cells, preventing binding of immune complexes containing autoantigens and inhibiting re-stimulation of immune cells. This down-regulates the B cells specifically involved in the autoimmune response, but does not affect B cells that are part of the normal immune response.

biocrea GMBH

biocrea GMBH, a 2010 management buy-out of Finland's Biotie Therapies, is developing phosphodiesterase inhibitors for diseases of the central nervous system, memory disorders and schizophrenia. Biocrea's novel approach to drug development may make it feasible to produce more specific inhibitors at the level of PDE subfamilies and/or isoforms, in order to optimize their efficacy and side-effect profiles.

Related Content

Related Companies

UsernamePublicRestriction

Register

OM003971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel